Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562915 | 1.00 | TAAR1 (0.42) | TAAR1MAOBLTA4HHTR2CSLC6A2 | |
| SCHEMBL4292539 | 1.00 | TAAR1 (0.42) | TAAR1MAOBLTA4HHTR2CSLC6A2 | |
| SCHEMBL14775161 | 0.84 | HRH3 (0.46) | TAAR1LTA4HHTR2CSLC6A2SLC6A4 | |
| SCHEMBL5563817 | 0.83 | TAAR1 (0.48) | TAAR1MAOBHTR2CSLC6A2SLC6A4 | |
| SCHEMBL5563826 | 0.83 | TAAR1 (0.48) | TAAR1MAOBHTR2CSLC6A2SLC6A4 | |
| SCHEMBL5177472 | 0.83 | LTA4H (0.41) | TAAR1MAOBLTA4H | |
| SCHEMBL5558447 | 0.83 | LTA4H (0.41) | TAAR1MAOBLTA4H | |
| SCHEMBL5563651 | 0.80 | LTA4H (0.41) | TAAR1LTA4H | |
| SCHEMBL5562744 | 0.80 | LTA4H (0.38) | LTA4H | |
| SCHEMBL5562735 | 0.80 | LTA4H (0.38) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1664063-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
| WO-2005026177-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1492794-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082877-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | HRH4, HRH2, HRH3 | TAAR1 247/4885MAOB 1656/4885LTA4H 1527/4885 |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | TAAR1 233/4885MAOB 438/4885LTA4H 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.